A Phase 3 interventional study of Beriplex® P/N (Kcentra) and Fresh frozen plasma in Blood Coagulation Disorders and Acute Major Bleeding, sponsored by CSL Behring. Completed at 69 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-03.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Blood Coagulation Disorders with a site in United States — 6 open to participants now, 6 under way, 2 of them phase 3. Blood Coagulation Disorders · United States.
Among the 55 studies in Blood Coagulation Disorders with a site in United States, this one is the 2nd largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2008, is one of 13 in phase 3, and was the 15th registered.
148 studies on the registry are indexed under Blood Coagulation Disorders; 16 are open to participants now.
Browse Blood Coagulation Disorders studies →6 of the 55 studies in Blood Coagulation Disorders with a site in United States are open now. Recruiting first, the newest first:
Hemab ApS · Sites in United States
Ages 12–70
Kedrion S.p.A. · Sites in United States, Czechia, Germany and 5 more countries
Ages 18–70
Vega Therapeutics, Inc · Sites in United States, Australia, Austria and 5 more countries
Ages 12–60 · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
University of Chicago · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Blood Coagulation Disorders studies recruiting now, 8 (62%) set no upper age limit and 4 (31%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 14 · Phase 4 4
First in 1999; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 216 is above the median of 50 across 79 interventional studies indexed under Blood Coagulation Disorders.
Median enrollment 33 across the 38 interventional studies, 120 across the 17 observational. Of the 40 that completed or were terminated, 18 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 3 studies filed under Blood Coagulation Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Blood Coagulation Disorders with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059000Phase 3Kedrion S.p.A.A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | 2026-12 |
| NCT01280825University of ChicagoThe 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing | 2027-11-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 55 studies in Blood Coagulation Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate efficacy, safety and tolerance of BERIPLEX® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by coumarin derivatives in subjects who require immediate correction of INR (International Normalized Ratio)and to stop an acute major bleeding.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Beriplex® P/N (Kcentra)
Biological: Fresh frozen plasma
Drug pages: Prothrombin complex concentrate · Four-factor Prothrombin Complex Concentrate
Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body weight
Also known as: Kcentra
Intravenous Infusion, dosage depending on baseline INR and body weight
Percentage of Participants Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed
Hemostatic efficacy was determined by a blinded independent board as excellent, good, or poor/none, based on prespecified definitions. Assessments of visible or non-visible musculoskeletal bleeding were made at 1 and 4 hours after the end of infusion. Hemostatic efficacy was the binary endpoint of effective or non-effective hemostasis, where 'effective' was a hemostatic efficacy rating of "excellent" or "good," and 'non-effective' was a hemostatic efficacy rating of "poor/none".
Time frame: At 1 and 4 hours after the end of infusion
Percentage of Participants Who Had a Rapid Decrease of the International Normalized Ratio (INR)
A rapid decrease of the international normalized ratio (INR) was defined as an INR ≤ 1.3 at 30 minutes after the end of the infusion. The INR is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy.
Time frame: 30 minutes after end of infusion
Percentage of Participants Who Had Hemostatic Efficacy for Visible or Non-visible Musculoskeletal Bleeding
Hemostatic efficacy was determined by a blinded independent board as excellent, good, or poor/none, based on prespecified definitions. Assessments of visible or non-visible musculoskeletal bleeding were made at 3 and 6 hours after the start of infusion. Hemostatic efficacy was the binary endpoint of effective or non-effective hemostasis, where 'effective' was a hemostatic efficacy rating of "excellent" or "good," and 'non-effective' was a hemostatic efficacy rating of "poor/none".
Time frame: At 3 and 6 hours after the start of infusion
Incremental in Vivo Recovery (IVR) (Response) of Factors II, VII, IX, and X, Protein C, and Protein S for Beriplex
The incremental IVR \[(IU/dL)/(IU/kg)\] was calculated as follows: (IU/dL activity rise in plasma)/(IU/kg body weight infused) = \[maximum increase in component plasma level within 3 hours compared to pre-infusion (IU/dL)\]/{\[exact dose of component in drug administered (IU)\]/\[body weight (kg)\]}.
Time frame: Before infusion and up to 3 h after the start of infusion
Plasma Levels of Factors II, VII, IX, and X, Protein C, and Protein S
Plasma levels are presented as the percentage of normal at pre-infusion and 30 min and 24 h after the start of infusion. The plasma level assay results are reported as a potency relative to a standard, where 100% is considered to be normal.
Time frame: From preinfusion until 24 h after the start of infusion
Percentage of Participants With INR Correction at Various Times After the Start of Infusion
The time taken from the start of infusion to INR correction (defined as an INR ≤ 1.3) was recorded. The percentage of participants with INR correction was calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion.
Time frame: From the start of infusion until INR correction; calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion.
Percentage of Participants With INR Correction at Various Times After Randomization
The time taken from randomization to INR correction (defined as an INR ≤ 1.3) was recorded. The percentage of participants with INR correction was calculated at 2.5, 3, 5, 8, 14, and 26 h after randomization.
Time frame: From randomization until INR correction; calculated at 2.5, 3, 5, 8, 14, and 26 h after randomization.
Transfusion of Red Blood Cells
Red blood cells were packed red blood cells (PRBCs).
Time frame: From the start of infusion until 24 h after the start of infusion
Use of Other Blood Products and Hemostatic Agents
Other blood products and hemostatic agents containing coagulation factors (such as whole blood, plasma, albumin, platelets) not including PRBCs.
Time frame: From the start of infusion until 24 h after the start of infusion
45-Day All-cause Mortality
Time frame: Until Day 45
Overall Treatment-emergent Adverse Events (TEAEs)
Number of participants with TEAEs. Treatment-related AEs were defined as events whose relationship to study treatment was definitely related, probably related, or possibly related in the opinion of the investigator. AEs with missing relationship were considered related to treatment. Serious TEAEs were treatment-emergent SAEs. Deaths reported up to and including Day 45; one additional Beriplex death occurred after Day 45.
Time frame: From the start of infusion up to the allowed time window of the Day 10 visit for non-serious AEs and from the start of infusion up to the allowed time window of the Day 45 visit for SAEs.
| Milestone | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Started | 107 | 109 |
| Completed | 82 | 92 |
| Not completed | 25 | 17 |
| Withdrew: Death / serious adverse event | 10 | 5 |
| Withdrew: Lost to follow-up | 9 | 4 |
| Withdrew: Withdrawal by subject | 3 | 7 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Intervention by primary care physician | 1 | 0 |
| Withdrew: Refused hospitalization | 1 | 0 |
Hemostatic efficacy was determined by a blinded independent board as excellent, good, or poor/none, based on prespecified definitions. Assessments of visible or non-visible musculoskeletal bleeding were made at 1 and 4 hours after the end of infusion. Hemostatic efficacy was the binary endpoint of effective or non-effective hemostasis, where 'effective' was a hemostatic efficacy rating of "excellent" or "good," and 'non-effective' was a hemostatic efficacy rating of "poor/none".
| percentage of participants | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Percentage of Participants Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed | 72.4 (63.6 to 81.3) | 65.4 (56.2 to 74.5) |
A rapid decrease of the international normalized ratio (INR) was defined as an INR ≤ 1.3 at 30 minutes after the end of the infusion. The INR is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy.
| percentage of participants | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Percentage of Participants Who Had a Rapid Decrease of the International Normalized Ratio (INR) | 62.2 (52.6 to 71.8) | 9.6 (3.9 to 15.3) |
Hemostatic efficacy was determined by a blinded independent board as excellent, good, or poor/none, based on prespecified definitions. Assessments of visible or non-visible musculoskeletal bleeding were made at 3 and 6 hours after the start of infusion. Hemostatic efficacy was the binary endpoint of effective or non-effective hemostasis, where 'effective' was a hemostatic efficacy rating of "excellent" or "good," and 'non-effective' was a hemostatic efficacy rating of "poor/none".
| percentage of participants | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Percentage of Participants Who Had Hemostatic Efficacy for Visible or Non-visible Musculoskeletal Bleeding | 73.5 (64.7 to 82.2) | 67.3 (58.3 to 76.3) |
The incremental IVR \[(IU/dL)/(IU/kg)\] was calculated as follows: (IU/dL activity rise in plasma)/(IU/kg body weight infused) = \[maximum increase in component plasma level within 3 hours compared to pre-infusion (IU/dL)\]/{\[exact dose of component in drug administered (IU)\]/\[body weight (kg)\]}.
| (IU/dL)/(IU/kg body weight) | Beriplex® P/N |
|---|---|
| Factor II | 2.00 ± 0.879 |
| Factor VII | 2.15 ± 2.958 |
| Factor IX | 1.29 ± 0.711 |
| Factor X | 1.96 ± 0.871 |
| Protein C | 2.04 ± 0.958 |
| Protein S | 2.17 ± 1.661 |
Plasma levels are presented as the percentage of normal at pre-infusion and 30 min and 24 h after the start of infusion. The plasma level assay results are reported as a potency relative to a standard, where 100% is considered to be normal.
| percentage of normal | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Factor II, pre-infusion (n = 98; 103) | 20.1 ± 14.56 | 22.3 ± 22.39 |
| Factor II, 0.5 h after infusion start (n = 88; 90) | 87.5 ± 44.48 | 31.9 ± 22.55 |
| Factor II, 24 h after infusion start (n = 92; 99) | 77.1 ± 22.06 | 58.1 ± 19.55 |
| Factor VII, pre-infusion (n = 98; 103) | 25.9 ± 35.01 | 23.5 ± 23.45 |
| Factor VII, 0.5h after infusion start (n = 88; 90) | 60.5 ± 45.23 | 34.6 ± 26.18 |
| Factor VII, 24 h after infusion start (n = 92; 99) | 114.8 ± 165.28 | 101.3 ± 79.01 |
| Factor IX, pre-infusion (n = 98; 103) | 36.1 ± 22.56 | 39.0 ± 27.56 |
| Factor IX, 0.5 h after infusion start (n = 88; 90) | 76.8 ± 35.47 | 47.7 ± 26.78 |
| Factor IX, 24 h after infusion start (n = 92; 99) | 88.5 ± 35.65 | 93.0 ± 29.95 |
| Factor X, pre-infusion (n = 98; 102) | 13.0 ± 11.25 | 14.7 ± 18.83 |
| Factor X, 0.5 h after infusion start (n = 88; 90) | 99.8 ± 56.07 | 23.9 ± 20.40 |
| Factor X, 24 h after infusion start (n = 92; 99) | 83.7 ± 27.05 | 58.2 ± 21.78 |
| Protein C, pre-infusion (n = 98; 103) | 39.3 ± 17.15 | 41.1 ± 18.84 |
| Protein C, 0.5 h after infusion start (n = 88; 90) | 110.3 ± 47.37 | 50.9 ± 24.78 |
| Protein C, 24h after infusion start (n = 92; 98) | 90.3 ± 27.19 | 82.8 ± 24.34 |
| Protein S, pre-infusion (n = 97; 102) | 27.8 ± 11.34 | 29.6 ± 12.97 |
| Protein S, 0.5 h after infusion start (n = 88; 89) | 59.4 ± 28.56 | 38.6 ± 20.45 |
| Protein S, 24 h after infusion start (n = 91; 97) | 47.8 ± 16.54 | 45.4 ± 16.00 |
The time taken from the start of infusion to INR correction (defined as an INR ≤ 1.3) was recorded. The percentage of participants with INR correction was calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion.
| percentage of participants | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| 0.5 h | 4 | 0 |
| 1 h | 69 | 0 |
| 3 h | 71 | 9 |
| 6 h | 78 | 16 |
| 12 h | 80 | 36 |
| 24 h | 88 | 58 |
The time taken from randomization to INR correction (defined as an INR ≤ 1.3) was recorded. The percentage of participants with INR correction was calculated at 2.5, 3, 5, 8, 14, and 26 h after randomization.
| percentage of participants | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| 2.5 h | 59 | 2 |
| 3 h | 67 | 2 |
| 5 h | 76 | 10 |
| 8 h | 79 | 22 |
| 14 h | 84 | 38 |
| 26 h | 90 | 70 |
Red blood cells were packed red blood cells (PRBCs).
| Units of PRBCs | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Transfusion of Red Blood Cells | 1.4 ± 1.77 | 1.2 ± 1.57 |
Other blood products and hemostatic agents containing coagulation factors (such as whole blood, plasma, albumin, platelets) not including PRBCs.
| Units of blood products | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Use of Other Blood Products and Hemostatic Agents | 0.3 ± 1.36 | 0.3 ± 0.87 |
| participants | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| 45-Day All-cause Mortality | 9 | 5 |
Number of participants with TEAEs. Treatment-related AEs were defined as events whose relationship to study treatment was definitely related, probably related, or possibly related in the opinion of the investigator. AEs with missing relationship were considered related to treatment. Serious TEAEs were treatment-emergent SAEs. Deaths reported up to and including Day 45; one additional Beriplex death occurred after Day 45.
| participants | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Any TEAE | 66 | 71 |
| At least possibly treatment-related TEAE | 10 | 23 |
| Serious TEAE | 32 | 26 |
| Death | 10 | 5 |
Collected over From the start of infusion up to the allowed time window of the Day 45 visit for SAEs, and from the start of infusion up to the allowed time window of the Day 10 visit for non-serious AEs.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Beriplex® P/N | — | 32/103 (31.1%) | 46/103 (44.7%) |
| Fresh Frozen Plasma | — | 26/109 (23.9%) | 40/109 (36.7%) |
| Event | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Cardiac failure congestiveCardiac disorders | 1/103 | 4/109 |
| Ischaemic strokeNervous system disorders | 3/103 | 0/109 |
| Atrial flutterCardiac disorders | 2/103 | 0/109 |
| Haemorrhage intracranialNervous system disorders | 2/103 | 0/109 |
| PneumoniaInfections and infestations | 2/103 | 1/109 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/103 | 1/109 |
| Myocardial ischaemiaCardiac disorders | 0/103 | 2/109 |
| EncephalopathyNervous system disorders | 0/103 | 2/109 |
| Subarachnoid haemorrhageNervous system disorders | 0/103 | 2/109 |
| AnaemiaBlood and lymphatic system disorders | 0/103 | 2/109 |
| Event | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| HeadacheNervous system disorders | 10/103 | 4/109 |
| ConstipationGastrointestinal disorders | 5/103 | 8/109 |
| Oedema peripheralGeneral disorders | 6/103 | 7/109 |
| InsomniaPsychiatric disorders | 6/103 | 3/109 |
| HypokalaemiaMetabolism and nutrition disorders | 2/103 | 6/109 |
| HypotensionVascular disorders | 5/103 | 3/109 |
| PyrexiaGeneral disorders | 4/103 | 4/109 |
| DizzinessNervous system disorders | 4/103 | 0/109 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 4/103 | 0/109 |
| TachycardiaCardiac disorders | 4/103 | 1/109 |
The Intention-to-treat population comprised all subjects who were (1) eligible for the study and had (2) signed informed consent and were randomized to 1 of the 2 treatment groups regardless of whether the subjects received study product. In the ITT population, subjects were analyzed "as randomized".
| Age, Customized(Participants) | Beriplex® P/N | Fresh Frozen Plasma | Total |
|---|---|---|---|
| < 65 years | 36 | 32 | 68 |
| ≥ 65 to < 75 years | 28 | 29 | 57 |
| ≥ 75 years | 43 | 48 | 91 |
| Sex: Female, Male(Participants) | Beriplex® P/N | Fresh Frozen Plasma | Total |
|---|---|---|---|
| Female | 52 | 55 | 107 |
| Male | 55 | 54 | 109 |
The record gives a start of Jun 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 2 years 9 months after primary completion. A results delay was requested in Jul 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Prothrombin complex concentrate · Four-factor Prothrombin Complex Concentrate